Bendamustine in combination with high-dose radiotherapy and thalidomide is effective in treatment of multiple myeloma with central nervous system involvement

被引：21
|
作者：
Nahi, Hareth [1 ]
Svedmyr, Erik [1 ]
Lerner, Richard [1 ]
机构：
[1] Karolinska Inst, Dept Med, Stockholm, Sweden
来源：
EUROPEAN JOURNAL OF HAEMATOLOGY | 2014年 / 92卷 / 05期
关键词：
THERAPY; AGENTS;
D O I：
10.1111/ejh.12247
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：454 / 455
页数：2
相关论文
共 46 条
  • [41] On-demand plerixafor added to high-dose cyclophosphamide and pegylated recombinant human granulocyte colony-stimulating factor in the mobilization of patients with multiple myeloma: a treatment with high effectiveness, convenient, and affordable cost
    Hou, Li-qiong
    Liu, Jun-Ru
    Gu, Jing-Li
    Chen, Mei-Lan
    Kuang, Li-Fen
    Huang, Bei-Hui
    Zou, Wai-yi
    Li, Juan
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [42] Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994-2004*
    Vangsted, Annette J.
    Klausen, Tobias W.
    Andersen, Niels F.
    Abildgaard, Niels
    Gang, Anne O.
    Gregersen, Henrik
    Vogel, Ulla
    Gimsing, Peter
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 85 (03) : 209 - 216
  • [43] R-MPV followed by high-dose chemotherapy with thiotepa-based and autologous stem cell transplantation for newly diagnosed primary central nervous system lymphoma: a single-center experience
    Lee, Ji Yun
    Paik, Jin Ho
    Suh, Koung Jin
    Kim, Ji-Won
    Kim, Se Hyun
    Kim, Jin Won
    Kim, Yu Jung
    Lee, Keun-Wook
    Kim, Jee Hyun
    Bang, Soo-Mee
    Lee, Jong-Seok
    Lee, Jeong-Ok
    BLOOD RESEARCH, 2021, 56 (04) : 285 - 292
  • [44] Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study
    Zeng, Zhiyong
    Yang, Apeng
    Yang, Jingke
    Zhang, Sheng
    Xing, Zhen
    Wang, Xingfu
    Mei, Wenzhong
    Jiang, Changzhen
    Lin, Junfang
    Wu, Xiyue
    Xue, Yihui
    Wu, Zanyi
    Yu, Lianghong
    Wang, Dengliang
    Chen, Jianwu
    Zheng, Shufa
    Lin, Qiaoxian
    Chen, Qingjiao
    Dong, Jinfeng
    Zheng, Xiaoqiang
    Wang, Jizhen
    Huang, Jinlong
    Chen, Zhenying
    Chen, Ping
    Zheng, Meihong
    Zhou, Xiaofang
    He, Youwen
    Lin, Yuanxiang
    Chen, Junmin
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [45] Phase 1 Study of the Combination of Escalated Total Marrow Irradiation Using Helical Tomotherapy and Fixed High-Dose Melphalan (140 mg/m2) Followed by Autologous Stem Cell Transplantation at First Relapse in Multiple Myeloma
    Cailleteau, Axel
    Maingon, Philippe
    Choquet, Sylvain
    Bourdais, Remi
    Antoni, Delphine
    Lioure, Bruno
    Hulin, Cyrille
    Batard, Stephanie
    Llagostera, Camille
    Guimas, Valentine
    Touzeau, Cyrille
    Moreau, Philippe
    Mahe, Marc-Andre
    Supiot, Stephane
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 115 (03): : 677 - 685
  • [46] Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry
    Zimmermann, Heiner
    Nitsche, Mirko
    Pott, Christiane
    Reinke, Petra
    Babel, Nina
    Hermann, Robert M.
    Hauser, Ingeborg A.
    Hahn, Dennis
    Ritgen, Matthias
    Pietschmann, Claudia
    Klapper, Wolfram
    Anagnostopoulos, Ioannis
    Trappe, Ralf U.
    ANNALS OF HEMATOLOGY, 2021, 100 (08) : 2043 - 2050
12345